Cumberland Pharmaceuticals (CPIX) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Grand Canyon Education places CFO on leave amid stock trade probe
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE
March 8, 2022 4:05 PM ESTNASHVILLE, Tenn., March 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced full year 2021 financial results and provided a company update. Net revenues totaled $36 million, resulting in $6 million in cash flow from operations.
